Vivos Therapeutics, Inc. VVOS
are a revenue stage medical technology and healthcare services company that features a comprehensive suite of proprietary
oral appliances and therapeutic treatments. Our products non-surgically treat certain maxillofacial and developmental
abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as mild to severe
obstructive sleep apnea (known as OSA) and snoring in adults. We call the use of our appliances coupled with specific therapeutic treatment protocols The Vivos Method.
Last close
0.13
2026-10-23
Market cap
$2.7M
2026-06-30 share count
52-week range
0.12 - 3.05
Valuation FY2025 figures against the last close
P/S0.2x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.07
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M | — |
| Cost of revenue | $6.9M | $6.0M | $5.5M | $200.0K | $400.0K | $100.0K | — | — |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M | $8.7M | — |
| R&D | $100.0K | $100.0K | $100.0K | $100.0K | $200.0K | — | — | — |
| SG&A | $27.7M | $17.9M | $22.5M | $29.0M | $25.8M | $16.1M | $16.2M | — |
| Total operating expenses | $30.4M | $20.2M | $25.6M | $35.0M | $33.0M | $22.5M | $19.2M | — |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M | -$12.0M | -$10.6M | — |
| Interest expense | $1.4M | — | — | — | $14.0K | $96.0K | $137.9K | — |
| Pre-tax income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$12.1M | -$10.8M | — |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$12.1M | -$10.8M | — |
| EPS, basic | -2.07 | -2.22 | -11.14 | -25.90 | -0.96 | — | — | — |
| EPS, diluted | -2.07 | -2.22 | -11.14 | -25.90 | -0.96 | -1.40 | -0.95 | — |
| Shares, diluted (wtd. avg.) | 10.3M | 5.0M | 1.2M | 920,592 | 21.23B | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.0M | $6.3M | $1.6M | $3.5M | $24.0M | $18.2M | $469.4K | — |
| Receivables | $1.6M | $430.0K | $202.0K | $457.0K | $1.2M | $1.4M | $871.3K | — |
| Total current assets | $4.4M | $7.5M | $2.5M | $5.4M | $27.3M | $20.4M | $2.0M | — |
| Property, plant and equipment | $3.8M | $3.3M | $3.3M | $3.1M | $2.8M | $872.0K | $1.1M | — |
| Goodwill | $8.6M | $2.8M | $2.8M | $2.8M | $2.8M | $2.7M | $2.7M | — |
| Other intangibles | $4.0M | $409.0K | $420.0K | $302.0K | $341.0K | $270.0K | $689.2K | — |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M | $25.3M | $7.6M | — |
| Accounts payable | $1.7M | $1.1M | $2.1M | $1.4M | $920.0K | $781.0K | $1.1M | — |
| Short-term debt | $8.4M | — | — | — | $1.3M | $867.0K | $3.7M | — |
| Total current liabilities | $18.1M | $5.0M | $7.3M | $6.8M | $7.5M | $7.8M | $9.1M | — |
| Long-term debt | $469.0K | — | — | — | $1.3M | $423.0K | $3.7M | — |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M | $8.4M | $9.2M | — |
| Retained earnings | -$125.4M | -$104.2M | -$93.1M | -$79.5M | -$55.6M | -$35.3M | -$23.3M | — |
| Total equity | -$1.5M | $8.0M | $411.0K | $4.8M | $25.5M | $16.9M | -$2.9M | $4.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M | -$5.7M | -$5.3M | — |
| Depreciation and amortisation | $1.3M | $581.0K | $621.0K | $669.0K | $733.0K | $300.0K | $326.8K | — |
| Stock-based compensation | $661.0K | $762.0K | $1.1M | $2.4M | $2.7M | $2.2M | $2.0M | — |
| Capital expenditure | $2.3M | $568.0K | $803.0K | $924.0K | $2.4M | $120.0K | $175.6K | — |
| Investing cash flow | -$7.5M | -$568.0K | -$853.0K | -$924.0K | -$2.6M | -$120.0K | $86.2K | — |
| Financing cash flow | $18.6M | $17.9M | $10.9M | — | $24.2M | $23.5M | $4.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-016854.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $11.4M | $13.1M | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Gross profit | — | $8.7M | $10.4M | $12.6M | $10.0M | $8.3M | $9.0M | $10.5M |
| Net income | — | -$10.8M | -$12.1M | -$20.3M | -$23.8M | -$13.6M | -$11.1M | -$21.2M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |